Our Pipeline

NOVEL TRPV1 AGONIST PRODRUGS FOR TREATING PAIN

Our pipeline consists of innovative non-opioid product candidates focused on managing pain from acute and chronic conditions where current options have resulted in significant unmet medical need.

Vocacapsaicin (CA-008), our most advanced product candidate for postsurgical pain is Phase 3 ready. It is a first-in-class prodrug therapeutic that rapidly converts to capsaicin, a potent TRPV1-agonist.

We are also actively developing product candidates to treat chronic pain conditions. CA-051 is specifically designed for epidural administration to treat refractory pain associated with cancer or following amputation.

In our third program, we are developing a novel injection product designed to treat chronic pain associated with moderate to severe osteoarthritis.

Our goal is to develop each of our products with patients’ needs at the center of our focus, and to deliver products with best-in-class therapeutic potential.